LRE90 and Diabetes

The effect of LRE90 on glycemic control in patients with type 2 diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200716048118N3

Enrollment

Registered

2026-02-10

Start date

2025-12-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Control group: Placebo is presented in the same shape, size, taste, smell, packaging, and method of administration as the drug. 4 tablets of 1000 mg of the placebo are prescribed twice

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients aged between 30 and 70 with HbA1c from 8 to 10 are included in the study

Exclusion criteria

Exclusion criteria: Pregnant women and those with breastfeeding patients with renal and liver failure patients with insulin therapy are excluded from the study

Design outcomes

Primary

Measure	Time frame
HbA1c. Timepoint: Three months. Method of measurement: Biochemical.	—

Secondary

Measure	Time frame
FBS. Timepoint: Three months. Method of measurement: Biochemical.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Bandarian

Tehran University of Medical Sciences

fbandarian@tums.ac.ir+98 21 8863 1296

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026